NeoGenomics (NASDAQ: NEO) to pay $9.8M in DOJ–OIG civil settlement
Rhea-AI Filing Summary
NeoGenomics, Inc. reported that it finalized a civil settlement with the U.S. Department of Justice, acting on behalf of OIG-HHS, resolving a government investigation into consulting services provided to certain health care providers under its Laboratory Collaboration Initiative program.
The company had voluntarily conducted an internal review of compliance with federal healthcare laws and self-disclosed the matter to OIG-HHS in November 2021. Under the settlement, NeoGenomics agreed to pay $9,813,260 plus interest at 4.250% per annum from January 16, 2026. As of March 31, 2026, it had accrued a reserve of $11.2 million for potential damages and liabilities associated with this investigation. The settlement agreement states it is neither an admission of liability by NeoGenomics nor a concession by the United States regarding its claims.
Positive
- None.
Negative
- NeoGenomics agreed to pay $9,813,260 plus 4.250% annual interest from January 16, 2026 to resolve a DOJ and OIG-HHS investigation into consulting services provided to certain health care providers, representing a material regulatory-related cash outflow.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Settlement payment: $9,813,260
Settlement interest rate: 4.250% per annum
Investigation reserve: $11.2 million
+2 more
5 metrics
Settlement payment
$9,813,260
Amount NeoGenomics agreed to pay under the civil settlement resolving the government investigation
Settlement interest rate
4.250% per annum
Interest on the settlement amount from January 16, 2026 until payment
Investigation reserve
$11.2 million
Reserve accrued as of March 31, 2026 for potential damages and liabilities tied to the investigation
Self-disclosure date
November 2021
Month and year NeoGenomics self-disclosed the matter to OIG-HHS
Settlement finalization date
June 20, 2026
Date the civil settlement with the DOJ, on behalf of OIG-HHS, was finalized
Key Terms
civil settlement, voluntarily conducted an internal investigation, fraud, waste and abuse, Laboratory Collaboration Initiative, +1 more
5 terms
civil settlement regulatory
"announced that it has finalized a civil settlement with the Department of Justice"
A civil settlement is an agreement reached between parties to resolve a non-criminal legal dispute without a trial, often involving a payment or corrective actions and typically without an admission of wrongdoing. For investors, settlements matter because they can create one-time costs, change future obligations, and affect a company’s reputation and regulatory risk—similar to paying a bill to avoid a long, uncertain courtroom fight.
voluntarily conducted an internal investigation regulatory
"the Company voluntarily conducted an internal investigation that focused on the compliance"
fraud, waste and abuse regulatory
"including those relating to fraud, waste and abuse."
Laboratory Collaboration Initiative medical
"for laboratory testing services as part of its Laboratory Collaboration Initiative program."
forward-looking statements regulatory
"This press release includes forward-looking statements."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What regulatory matter did NeoGenomics (NEO) resolve with the DOJ and OIG-HHS?
NeoGenomics resolved a government investigation through a civil settlement with the DOJ, acting on behalf of OIG-HHS, related to consulting services provided to certain health care providers under its Laboratory Collaboration Initiative program for laboratory testing services.
How much will NeoGenomics (NEO) pay under the DOJ and OIG-HHS settlement?
NeoGenomics agreed to pay $9,813,260 plus interest at 4.250% per annum from January 16, 2026. This payment resolves the government’s investigation into consulting services provided to certain health care providers in connection with its Laboratory Collaboration Initiative program.
What reserve had NeoGenomics (NEO) recorded for this investigation?
As of March 31, 2026, NeoGenomics had accrued a reserve of $11.2 million for potential damages and liabilities associated with the investigation. This reserve was previously disclosed in its SEC reports and relates directly to the consulting-services matter covered by the settlement.
When did NeoGenomics (NEO) voluntarily disclose the consulting-services issue to OIG-HHS?
NeoGenomics self-disclosed the matter to OIG-HHS in November 2021 after conducting an internal investigation into the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse.
Does the DOJ settlement mean NeoGenomics (NEO) admitted liability?
No. The settlement agreement explicitly states it is neither an admission of liability by NeoGenomics nor a concession by the United States that its claims are not well founded. It is a civil resolution of the government’s investigation into the company’s consulting services.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | ||||||||||
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||||||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||||||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||||||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 | Regulation FD Disclosure. | ||||
On June 20, 2026, NeoGenomics, Inc. (the “Company”) issued a press release in connection with the settlement agreement described in Item 8.01 below.
The information in Item 7.01 of this Current Report and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 8.01 | Other Events. | ||||
As previously disclosed, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. The Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG-HHS”) of the internal investigation in November 2021.
On June 20, 2026, the Company finalized a civil settlement with the U.S. Department of Justice (“DOJ”), acting on behalf of the OIG-HHS, resolving the U.S. government’s investigation concerning consulting services provided by the Company to certain health care providers, as described above. Pursuant to the terms of the settlement agreement, the Company has agreed to pay $9,813,260 to resolve the matter. As previously disclosed, as of March 31, 2026, the Company had accrued a reserve of $11.2 million for potential damages and liabilities associated with the matters identified during the course of the investigation.
The settlement agreement is neither an admission of liability by the Company nor a concession by the United States that its claims are not well founded.
| Item 9.01 | Financial Statements and Exhibits. | ||||
(a) | Not applicable | |||||||
(b) | Not applicable | |||||||
(c) | Not applicable | |||||||
(d) | Exhibits. | |||||||
99.1 | Press Release of NeoGenomics, Inc. dated July 20, 2026 | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEOGENOMICS, INC. | |||||||||||||||||
| Date: | July 20, 2026 | By: | /s/ Alicia C. Olivo | ||||||||||||||
| Name: | Alicia C. Olivo | ||||||||||||||||
| Title: | Executive Vice President, General Counsel & Secretary | ||||||||||||||||
Exhibit 99.1
July 20, 2026 |  | ||||
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the Department of Justice (“DOJ”) on behalf of the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG”) resolving an investigation concerning consulting services provided by the Company to certain health care providers for laboratory testing services as part of its Laboratory Collaboration Initiative program. The Company self-disclosed the matter to the OIG in November 2021. As the DOJ acknowledged in the settlement agreement, the Company cooperated with the government’s investigation into the matter.
The Company has agreed to pay $9,813,260 plus interest at a rate of 4.250% per annum from January 16, 2026 to the United States o resolve the matter. The Company previously disclosed in its SEC filings that it had accrued a reserve of $11.2 million to cover potential damages and liabilities associated with the investigation.
Tony Zook, Chief Executive Officer, commented, “We are pleased to resolve this legacy matter. The resolution of this voluntary disclosure will allow the Company to continue moving forward with its vision and commitment to advancing personalized cancer care.”
The Settlement Agreement is neither an admission of liability by the Company nor a concession by the United States that its claims are not well founded.
About NeoGenomics
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.
Forward Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. Each forward-looking statement contained in this press release, including statements regarding the expected impact of the settlement, is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the risks identified under the heading "Risk Factors" contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company’s other filings with the Securities and Exchange Commission.
Exhibit 99.1
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Media Contact
Andrea Sampson asampson@sampsonprgroup.com
Investor Contact
InvestorRelations@neogenomics.com